- No file added yet -

Cost–effectiveness of adjuvant atezolizumab for patients with stage II–IIIA PD-L1+ non-small-cell lung cancer. Supplementary material

dataset

posted on 2023-04-06, 11:36 authored by Janet S Lee, Jan Bhagwakar, Caroline Nguyen, Ann Johnson, Nick Jovanoski, Sarika Ogale, Millie Das

Supplementary data

History

Usage metrics

Categories

Keywords

non-small-cell lung cancer immunotherapy health technology assessment health economics cost–effectiveness atezolizumab

Licence

CC BY-NC-ND 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC